Linkedin Facebook Twitter Youtube

22 Jul PolTREG

Posted at 20:08h in by

Daniel Shelly, Ph.D., Chief Business Development Officer

Oct. 8 | 4:30pm | FLW Ballroom F 

Gdansk Poland

(NASDAQ: PTG)

PolTREG is an advanced clinical stage company based in Poland developing engineered and polyclonal Tregulatory cell therapies for Autoimmune disease. Our lead Treg asset, PTG-007, has been evaluated in over 101 patients, in 4 clinical studies, across three indications. PTG-007 is ready to enter pivotal studies in T1D. We are also developing next-generation antigen specific, CAR, and TCR-Tregs including Allogenic Treg cell therapies. PolTREG has also built a state of the art cGMP cell therapy manufacturing facility in Gdansk to supply clinical to commercial scale production of Tregs. While fully allogeneic therapies are 10 years away, PolTREG will commercialize polyclonal Tregs in the near term while working towards the same goal of off-the-shelf Tregulatory cell therapies.

www.poltreg.com



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 6-8, 2025
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions